

OREXO'S NOMINATION COMMITTEE PROPOSES DR. FRIEDRICH VON BOHLEN UND HALBACH AS A NEW MEMBER OF THE BOARD

Uppsala, Sweden – November 21, 2024 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces that the company's Nomination Committee proposes the election of Dr. Friedrich von Bohlen und Halbach as a new member of the Board of Directors, and that the Board of Directors thus shall consist of six Board Members. The proposal will be presented at an Extraordinary General Meeting to be held on 18 December 2024, for which notice will be published shortly.

German-based Friedrich von Bohlen has more than 25 years of experience in a number of successful national and international biotech companies, in several of which he has played a decisive role in their growth as co-founder and/or CEO or Chairman. He has been part of IPOs in Europe and in the US and has broad investment experience in the global biotech sector. Today Friedrich von Bohlen is CEO of Molecular Health GmbH and member of two Boards. Friedrich von Bohlen holds a PhD in Neurobiology from the Swiss Federal Institute of Technology, Switzerland, and a Diploma in Biochemistry from the University of Zurich, Switzerland.

James Noble, Chairman of the Board, and member of the Nomination Committee said:

"I am pleased to propose Dr. Friedrich von Bohlen as a new member of the Board. Friedrich von Bohlen has an impressive background in strategic management, business development, and partnerships, along with substantial experience in development of new innovative pharmaceuticals. His valuable insights, entrepreneurial mindset, and extensive professional network will significantly contribute to Orexo's accelerated strategic development and enhance the potential of our world-class drug delivery technology, AmorphOX®. Upon his election to the Board, I would like to warmly welcome Friedrich von Bohlen, who will be instrumental in advancing our company to the next level."

The Nomination Committee has informed that it intends to propose Friedrich von Bohlen as new Chairman of the Board at the Annual General Meeting 2025, when James Noble has announced his retirement as Chairman of the Board.

For further information contact:

Orexo AB (publ.)

Nikolaj Sørensen, President and CEO
Lena Wange, IR & Communications Director
Tel: +46 (0) 18 780 88 00
E-mail: ir@orexo.com

About Orexo

Orexo is a Swedish pharmaceutical company with 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2023 amounted to SEK 639 million, and the number of employees to 116. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX (ORXOY) in the US.

For more information about Orexo please visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube.

The information was submitted for publication at 5.30 pm CET on November 21, 2024.

Attachments

[Orexo's Nomination Committee proposes Dr. Friedrich von Bohlen und Halbach as a new member of the Board](#)